COGT
Cogent Biosciences, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Mar 31 ▼ 1 insider sell $242.6M at $34.66
- Apr 1 ▲ Cogent Biosciences announced the submission of a New Drug Applicatio…
- May 28 ▲ Cogent Biosciences announced FDA acceptance of its NDA for bezuclast…
- May 28 FDA: Cogent Biosciences Announces FDA Acceptance of New Drug Ap…
- May 30 ▲ Cogent Biosciences reported highly positive Phase 3 PEAK trial resul…
- May 30 FDA: Cogent Biosciences Announces Detailed Clinical Data from P…
- Jun 12 FDA: Cogent Biosciences Announces Preclinical Data from Novel J…
- Jun 12 ▲ Cogent Biosciences reported updated Phase 2 APEX trial results for b…
- Jun 12 FDA: Cogent Biosciences Announces Detailed Data from APEX Pivot…
- Aug 9 ▲ 14 active institutional managers accumulated $112.2M net in COGT dur…
- Aug 27 ▼ 1 insider sell $1.7M at $37.12
- Sep 30 ▲ 3 funds open new positions (13F)
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $244.3M.
- InstitutionsBULLISH
Q3 2026: 38 added (3 new), 17 trimmed or exited. Largest new: Loomis Sayles & L P $35.7M, Hrt Financial $10.1M.
- AnalystsBULLISH
16 of 18 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −11.4% to 17.42M shares. 8.7 days to cover, ≈10.0% of shares.
- TrendRANGE
12% below its 50-day average. New closing low $27.44 on Nov 16.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FRANKLIN TEMPLETON INC | DOUBLED | $61.0M |
| UBS Group AG | ADD | $53.7M |
| LOOMIS SAYLES & CO L P | NEW | $35.7M |
| Nuveen, LLC | ADD | $28.0M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | $22.7M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $21.1M |
| Aberdeen Group plc | ADD | $18.8M |
| MORGAN STANLEY | TRIM | $16.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
18 analystsPrice is below the lowest target. Median implies +100%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 9, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Sep 16, 2026 | Wedbush REITERATE | Outperform |
| Sep 15, 2026 | HC Wainwright & Co. REITERATE | Buy |
| Aug 17, 2026 | Piper Sandler MAINTAIN | Overweight |
| Aug 12, 2026 | Guggenheim MAINTAIN | Buy |
| May 29, 2026 | Wedbush REITERATE | Outperform |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Ferrante Karen Jean Director Oct 1, 2026 | AWARD | 759 sh |
Morris Arlene Director Aug 27, 2026 | SELL | $118.7K |
Morris Arlene Director Aug 27, 2026 | EXERCISE | $9.0K |
Morris Arlene Director Aug 27, 2026 | EXERCISE | $236.5K |
Morris Arlene Director Aug 27, 2026 | SELL | $1.6M |
Ferrante Karen Jean Director Jul 1, 2026 | AWARD | 627 sh |
Ros Matthew Director Jun 9, 2026 | AWARD | 17,901 sh |
Harwin Peter Evan Director Jun 9, 2026 | AWARD | 17,901 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | -$2.33 | -$2.53–-$2.02 | -5.4% | $5.2M |
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
7 filings · 6 press releases · 1 bullish · 0 bearish · 6 neutral- NEUTRAL INST-CLUSTERNov 9, 2026
Seven institutional investors added $16.3M in net new COGT positions during Q3 2026, while two…
The cluster's net buying suggests institutional positioning ahead of the upcoming PDUFA catalysts. However, the 45-day reporting lag means these positions may have been adjusted since quarter-end…
- NEUTRAL 8-KNov 5, 2026
Cogent Biosciences reported Q3 2026 net loss of $111.4M, wider than the $80.9M loss in Q3 2025…
The key catalyst is the GIST PDUFA date on Nov 30, 2026, just 25 days away. Approval would trigger a commercial launch and potential revenue inflection. Monitor FDA decision and any advisory…
- NEUTRAL PRESS-RELEASENov 5, 2026
Cogent Biosciences reported Q3 2026 net loss of $111.4M, wider than the $80.9M loss in Q3 2025…
The key catalyst is the November 30 PDUFA date for bezuclastinib in GIST; approval would trigger a commercial launch and potential revenue inflection. Monitor the ASH 2026 presentations (Dec 12-15)…
- NEUTRAL 8-KAug 10, 2026
Cogent Biosciences reported a wider net loss of $96.4M for Q2 2026 vs. $73.5M a year ago…
The binary catalysts are the November and December 2026 PDUFA decisions for bezuclastinib in GIST and NonAdvSM. Positive outcomes would validate a multi-billion-dollar peak sales opportunity; any…
All COGT filing & press-release reports (13)
- INST-CLUSTER reportNov 9, 2026
- 8-K reportNov 5, 2026
- PRESS-RELEASE reportNov 5, 2026
- PRESS-RELEASE reportAug 10, 2026
- 8-K reportAug 10, 2026
- INST-CLUSTER reportAug 9, 2026
- PRESS-RELEASE reportJun 12, 2026
- PRESS-RELEASE reportJun 12, 2026
- PRESS-RELEASE reportMay 30, 2026
- PRESS-RELEASE reportMay 28, 2026
- 8-K reportMay 5, 2026
- PRESS-RELEASE reportApr 17, 2026
- PRESS-RELEASE reportApr 1, 2026